Skip to main content

MoneyWorks4Me

Lupin eyeing $54 billion complex generics market: Report

11 Jan 2018 Evaluate

Lupin is reportedly targeting for $54 billion complex generics market as it tries to insulate itself from increasing competition and consolidation of distribution channel in US in plain vanilla copycat drugs. Of $98 billion products under development, 55% will come from complex categories like biosimilars, inhalation, depot injectables, opthalmic and topical dermatological drugs.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Peers
Company Name CMP
Sun Pharma. Inds. 1870.05
Dr. Reddys Labs. 1387.00
Cipla 1383.00
Lupin 1953.90
Zydus Lifesciences 1202.70
View more..